Morepen Laboratories Limited (BOM:500288)
35.57
+0.94 (2.71%)
At close: Jan 22, 2026
Morepen Laboratories Revenue
Morepen Laboratories had revenue of 4.16B INR in the quarter ending September 30, 2025, a decrease of -5.99%. This brings the company's revenue in the last twelve months to 17.56B, down -1.05% year-over-year. In the fiscal year ending March 31, 2025, Morepen Laboratories had annual revenue of 18.12B with 7.17% growth.
Revenue (ttm)
17.56B
Revenue Growth
-1.05%
P/S Ratio
1.07
Revenue / Employee
9.68M
Employees
1,814
Market Cap
18.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 18.12B | 1.21B | 7.17% |
| Mar 31, 2024 | 16.90B | 2.68B | 18.88% |
| Mar 31, 2023 | 14.22B | -1.34B | -8.60% |
| Mar 31, 2022 | 15.56B | 3.58B | 29.87% |
| Mar 31, 2021 | 11.98B | 3.40B | 39.57% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 22.26B |
| Hikal | 16.99B |
| Gufic Biosciences | 8.74B |
| Bliss GVS Pharma | 8.60B |
| TTK Healthcare | 8.25B |
| Venus Remedies | 6.99B |
| Syncom Formulations (India) | 5.15B |
| Amrutanjan Health Care | 4.70B |
Morepen Laboratories News
- 7 weeks ago - Morepen Laboratories receives GST show-cause notice alleging excess refund claim of ₹117.94 crore - Business Upturn
- 2 months ago - Morepen Laboratories secures Rs 50 crore unsecured term loan from Kookmin Bank - Business Upturn
- 4 months ago - Morepen Laboratories shares rally over 4% after company forms 50:50 Joint Venture with UAE’s Bimedical FZE - Business Upturn
- 4 months ago - Morepen Laboratories subsidiary to form 50:50 JV with UAE’s Bimedical FZE for medical devices business - Business Upturn
- 6 months ago - Morepen Laboratories shares drop 4% as Q1 net profit drops 68.5% YoY to Rs 11.4 crore - Business Upturn
- 6 months ago - Morepen Laboratories Q1 Results: Net profit plunges 68% YoY to Rs 11.4 crore, revenue down 6.6% YoY - Business Upturn
- 8 months ago - Morepen Laboratories secures Rs 50 crore loan facility from Qatar National Bank - Business Upturn
- 9 months ago - Morepen Laboratories share price drops 3% as Q4 Ebitda falls 12.6% to Rs 42.3 crore - Business Upturn